Peer-Reviewed Publication
Diabetes Obes Metab2021;23(2):599-608.February 1, 2021Journal Article
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
Torben Biester1, Ido Muller2, Thekla von dem Berge1, Eran Atlas2, Revital Nimri3, Moshe Phillip3,4, Tadej Battelino5,6, Natasa Bratina5,6, Klemen Dovc5,6, Markus F Scheerer7, Olga Kordonouri1, Thomas Danne1
1Diabetes Centre for Children and Adolescents, Kinder und Jugendkrankenhaus, Auf der Bult, Hannover, Germany.
2DreaMed Diabetes Ltd, Petah Tikva, Israel.
3The Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Centre for Childhood Diabetes, Schneider Children's Medical Centre of Israel, Petah Tikva, Israel.
4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
5Department of Paediatric Endocrinology, Diabetes and Metabolic Diseases, UMC - University Children's Hospital, Ljubljana, Slovenia.
6Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
7AstraZeneca, Wedel, Germany.
Abstract
AIM: To investigate the effect of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on glucose levels overnight and during the following day after two unannounced meals under full closed loop (FCL) conditions.
MATERIALS AND METHODS: For this single-centre, double-blind, randomized, placebo-controlled, cross-over trial, non-obese persons with type 1 diabetes (T1D) were studied twice (10…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans